Redhawk Wealth Advisors Inc. Has $2.08 Million Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Redhawk Wealth Advisors Inc. lowered its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 14.3% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 32,592 shares of the biopharmaceutical company's stock after selling 5,443 shares during the quarter. Redhawk Wealth Advisors Inc.'s holdings in Halozyme Therapeutics were worth $2,080,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in HALO. State of Alaska Department of Revenue boosted its stake in Halozyme Therapeutics by 213.4% in the 4th quarter. State of Alaska Department of Revenue now owns 46,508 shares of the biopharmaceutical company's stock worth $2,222,000 after purchasing an additional 31,670 shares during the period. Shaker Investments LLC OH boosted its position in shares of Halozyme Therapeutics by 12.3% during the fourth quarter. Shaker Investments LLC OH now owns 75,326 shares of the biopharmaceutical company's stock worth $3,601,000 after buying an additional 8,249 shares during the period. Louisiana State Employees Retirement System grew its holdings in shares of Halozyme Therapeutics by 0.6% during the fourth quarter. Louisiana State Employees Retirement System now owns 35,300 shares of the biopharmaceutical company's stock worth $1,688,000 after buying an additional 200 shares in the last quarter. Davidson Capital Management Inc. raised its position in Halozyme Therapeutics by 111.2% in the 4th quarter. Davidson Capital Management Inc. now owns 56,639 shares of the biopharmaceutical company's stock valued at $2,708,000 after buying an additional 29,826 shares during the last quarter. Finally, Castellan Group raised its position in Halozyme Therapeutics by 2.3% in the 4th quarter. Castellan Group now owns 116,470 shares of the biopharmaceutical company's stock valued at $5,568,000 after buying an additional 2,672 shares during the last quarter. Institutional investors and hedge funds own 97.79% of the company's stock.

Insiders Place Their Bets

In other news, Director Jeffrey William Henderson sold 503 shares of Halozyme Therapeutics stock in a transaction on Tuesday, April 1st. The stock was sold at an average price of $64.05, for a total value of $32,217.15. Following the transaction, the director now owns 33,108 shares in the company, valued at approximately $2,120,567.40. This trade represents a 1.50% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 2.40% of the company's stock.

Halozyme Therapeutics Stock Performance

NASDAQ HALO traded up $0.07 on Thursday, reaching $53.92. The stock had a trading volume of 439,131 shares, compared to its average volume of 1,631,419. The firm has a fifty day moving average of $57.51 and a two-hundred day moving average of $55.99. The company has a market cap of $6.64 billion, a P/E ratio of 15.72, a price-to-earnings-growth ratio of 0.42 and a beta of 1.19. Halozyme Therapeutics, Inc. has a 1-year low of $42.01 and a 1-year high of $70.51. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.98 by $0.13. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The firm had revenue of $264.86 million during the quarter, compared to the consensus estimate of $231.21 million. During the same quarter in the previous year, the firm posted $0.79 EPS. The business's revenue for the quarter was up 35.2% compared to the same quarter last year. On average, equities research analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on HALO. Benchmark downgraded shares of Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Wednesday, May 7th. JPMorgan Chase & Co. lifted their price target on shares of Halozyme Therapeutics from $55.00 to $58.00 and gave the company a "neutral" rating in a research note on Monday, April 21st. Wells Fargo & Company increased their price objective on shares of Halozyme Therapeutics from $60.00 to $65.00 and gave the stock an "equal weight" rating in a research note on Wednesday, May 7th. Leerink Partnrs downgraded Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Tuesday, May 13th. Finally, Morgan Stanley cut Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and reduced their price target for the company from $73.00 to $62.00 in a research report on Wednesday, May 14th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, Halozyme Therapeutics presently has an average rating of "Hold" and a consensus target price of $61.90.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.